Published in Antisense Nucleic Acid Drug Dev on August 01, 2000
Derivation of normal macrophages from human embryonic stem (hES) cells for applications in HIV gene therapy. Retrovirology (2006) 1.21
Delta ribozyme benefits from a good stability in vitro that becomes outstanding in vivo. RNA (2002) 1.13
CXCR4 and CCR5 shRNA transgenic CD34+ cell derived macrophages are functionally normal and resist HIV-1 infection. Retrovirology (2005) 1.10
HIV-1 resistance conferred by siRNA cosuppression of CXCR4 and CCR5 coreceptors by a bispecific lentiviral vector. AIDS Res Ther (2005) 1.05
Stem cell-based anti-HIV gene therapy. Virology (2011) 0.94
Lentiviral transduction of Tar Decoy and CCR5 ribozyme into CD34+ progenitor cells and derivation of HIV-1 resistant T cells and macrophages. AIDS Res Ther (2004) 0.92
Activity of HDV ribozymes to trans-cleave HCV RNA. World J Gastroenterol (2002) 0.85
Current progress and challenges in HIV gene therapy. Future Virol (2011) 0.82
RNA-based gene therapy for the treatment and prevention of HIV: from bench to bedside. Yale J Biol Med (2011) 0.82
Combinatorial RNA-based gene therapy for the treatment of HIV/AIDS. Expert Opin Biol Ther (2013) 0.81
Functional and intracellular localization properties of U6 promoter-expressed siRNAs, shRNAs, and chimeric VA1 shRNAs in mammalian cells. RNA (2008) 0.77
Stem cell-based therapies for HIV/AIDS. Adv Drug Deliv Rev (2016) 0.77
RNase P-associated external guide sequence effectively reduces the expression of human CC-chemokine receptor 5 and inhibits the infection of human immunodeficiency virus 1. Biomed Res Int (2012) 0.76
The feasibility of incorporating Vpx into lentiviral gene therapy vectors. Mol Ther Methods Clin Dev (2016) 0.75
Synthesis and use of synthetic oligonucleotides. Annu Rev Biochem (1984) 4.53
Ribozymes as potential anti-HIV-1 therapeutic agents. Science (1990) 4.49
Ribozyme-mediated inhibition of HIV 1 suggests nucleolar trafficking of HIV-1 RNA. Proc Natl Acad Sci U S A (2000) 1.88
The expression cassette determines the functional activity of ribozymes in mammalian cells by controlling their intracellular localization. RNA (1997) 1.84
Direct detection of HIV-1 RNA from AIDS and ARC patient samples. DNA (1988) 1.79
Facilitation of hammerhead ribozyme catalysis by the nucleocapsid protein of HIV-1 and the heterogeneous nuclear ribonucleoprotein A1. EMBO J (1994) 1.77
Inhibition of human immunodeficiency virus by using an oligonucleoside methylphosphonate targeted to the tat-3 gene. J Virol (1988) 1.73
Expression of small, therapeutic RNAs in human cell nuclei. Gene Ther (1997) 1.71
Unexpected point mutations activate cryptic 3' splice sites by perturbing a natural secondary structure within a yeast intron. Genes Dev (1991) 1.70
Structure and organization of the two tRNATyr gene clusters on the E. coli chromosome. Cell (1979) 1.68
An alternate method for synthesis of double-stranded DNA segments. J Biol Chem (1982) 1.63
The first ATPase domain of the yeast 246-kDa protein is required for in vivo unwinding of the U4/U6 duplex. RNA (1999) 1.62
Partial purification and some properties of delta1-pyrroline-5-carboxylate reductase from Escherichia coli. J Bacteriol (1977) 1.49
Differential transcription of Pgk genes during spermatogenesis in the mouse. Dev Biol (1992) 1.41
Proline excretion and indirect suppression in Escherichia coli and Salmonella typhimurium. J Bacteriol (1974) 1.41
Detection of drug resistance in human tumors by in vitro enzymatic amplification. Cancer Res (1988) 1.40
Differential recovery of auxotrophs after penicillin enrichment in Escherichia coli. J Bacteriol (1971) 1.39
Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein. Proc Natl Acad Sci U S A (1991) 1.37
Progress and prospects: RNA-based therapies for treatment of HIV infection. Gene Ther (2007) 1.34
Biological expression of an Escherichia coli consensus sequence promoter and some mutant derivatives. Proc Natl Acad Sci U S A (1983) 1.33
Engineering and optimization of the miR-106b cluster for ectopic expression of multiplexed anti-HIV RNAs. Gene Ther (2008) 1.32
RNA accessibility prediction: a theoretical approach is consistent with experimental studies in cell extracts. Nucleic Acids Res (2000) 1.27
Foamy combinatorial anti-HIV vectors with MGMTP140K potently inhibit HIV-1 and SHIV replication and mediate selection in vivo. Gene Ther (2009) 1.27
A test for intron function in the yeast actin gene. Nature (1985) 1.24
Chimeric DNA-RNA hammerhead ribozymes have enhanced in vitro catalytic efficiency and increased stability in vivo. Nucleic Acids Res (1992) 1.24
Identification and characterization of yeast mutants that overcome an experimentally introduced block to splicing at the 3' splice site. RNA (1996) 1.24
Yeast pre-messenger RNA splicing efficiency depends on critical spacing requirements between the branch point and 3' splice site. EMBO J (1986) 1.22
Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-tat and rev hammerhead ribozymes. Gene (1994) 1.13
Lentiviral-mediated delivery of siRNAs for antiviral therapy. Gene Ther (2006) 1.11
Structural organization of Escherichia coli tRNAtyr gene clusters in four different transducing bacteriophages. J Mol Biol (1979) 1.10
Allogeneic bone marrow transplantation, zidovudine, and human immunodeficiency virus type 1 (HIV-1) infection. Studies in a patient with non-Hodgkin lymphoma. Ann Intern Med (1989) 1.08
Oligonucleotide probes for the detection of TEM-1 and TEM-2 beta-lactamase genes and their transposons. Can J Microbiol (1987) 1.06
Inhibition of bcr-abl oncogene expression by novel deoxyribozymes (DNAzymes). Hum Gene Ther (1999) 1.04
Isolation and functional analysis of a Kluyveromyces lactis RAP1 homologue. Gene (1994) 1.02
Detection of antisense and ribozyme accessible sites on native mRNAs: application to NCOA3 mRNA. Mol Ther (2001) 1.00
Kluyveromyces lactis maintains Saccharomyces cerevisiae intron-encoded splicing signals. Mol Cell Biol (1989) 0.98
Isolation of a mouse pseudo tRNA gene encoding CCA--a possible example of reverse flow of genetic information. Nature (1982) 0.97
Rapid determination and quantitation of the accessibility to native RNAs by antisense oligodeoxynucleotides in murine cell extracts. Nucleic Acids Res (1998) 0.97
Ribozyme-mediated inhibition of bcr-abl gene expression in a Philadelphia chromosome-positive cell line. Blood (1993) 0.95
Current progress in the development of RNAi-based therapeutics for HIV-1. Gene Ther (2011) 0.93
Intracellular applications of ribozymes. Methods Enzymol (2001) 0.92
Proline excretion in Escherichia coli: a comparison of an argD+ strain and a proline-excreting argD- derivative. Biochem Genet (1977) 0.91
Ribozyme-mediated cleavage of an HIV-1 gag RNA: the effects of nontargeted sequences and secondary structure on ribozyme cleavage activity. Antisense Res Dev (1991) 0.91
Biological and functional aspects of catalytic RNAs. Crit Rev Eukaryot Gene Expr (1992) 0.91
Effect of enrichment procedure upon auxotroph recovery in Escherichia coli K-12. Antimicrob Agents Chemother (1975) 0.91
Ribozyme-mediated inhibition of rat leukocyte-type 12-lipoxygenase prevents intimal hyperplasia in balloon-injured rat carotid arteries. Circulation (2001) 0.90
Use of polymerase chain reaction to detect the expression of the Mr 70,000 heat shock genes in control or heat shock leukemic cells as correlated to their heat response. Cancer Res (1990) 0.89
Adenoviral delivery of a leukocyte-type 12 lipoxygenase ribozyme inhibits effects of glucose and platelet-derived growth factor in vascular endothelial and smooth muscle cells. Circ Res (2001) 0.87
Detection by enzymatic amplification of bcr-abl mRNA in peripheral blood and bone marrow cells of patients with chronic myelogenous leukemia. Blood (1989) 0.86
Ribozyme-mediated RNA degradation in nuclei suspension. Nucleic Acids Res (1995) 0.86
RNAi therapeutics: SNALPing siRNAs in vivo. Gene Ther (2006) 0.86
Ribozymes: use as anti-HIV therapeutic molecules. Antisense Res Dev (1993) 0.85
Innate immunity confounds the clinical efficacy of small interfering RNAs (siRNAs). Gene Ther (2009) 0.85
Protecting from R5-tropic HIV: individual and combined effectiveness of a hammerhead ribozyme and a single-chain Fv antibody that targets CCR5. Gene Ther (2004) 0.85
Status of ribozyme and antisense-based developmental approaches for anti-HIV-1 therapy. Ann N Y Acad Sci (1992) 0.85
Arginine side-chain dynamics in the HIV-1 rev-RRE complex. J Mol Biol (2000) 0.84
Substitution of non-catalytic stem and loop regions of hammerhead ribozyme with DNA counterparts only increases KM without sacrificing the catalytic step (kcat): a way to improve substrate-specificity. Nucleic Acids Symp Ser (1992) 0.84
Enhancement of ribozyme function by RNA binding proteins. Methods Mol Biol (1997) 0.84
Monitoring retroviral RNA dimerization in vivo via hammerhead ribozyme cleavage. J Virol (1998) 0.84
Oligonucleotide scanning of native mRNAs in extracts predicts intracellular ribozyme efficiency: ribozyme-mediated reduction of the murine DNA methyltransferase. Mol Ther (2000) 0.84
An inexpensive membrane filtration manifold. Anal Biochem (1975) 0.83
Stem cells, ribozymes and HIV. Gene Ther (2009) 0.83
Intracellular ribozyme applications. Biochem Soc Trans (2002) 0.83
Evidence that a leukocyte type of 12-lipoxygenase is expressed and regulated by angiotensin II in human adrenal glomerulosa cells. Endocrinology (1994) 0.82
Correlation of activity with stability of chemically modified ribozymes in nuclei suspension. Antisense Nucleic Acid Drug Dev (1996) 0.82
In vivo, high-resolution analysis of yeast and mammalian RNA-protein interactions, RNA structure, RNA splicing and ribozyme cleavage by use of terminal transferase-dependent PCR. Nucleic Acids Res (2000) 0.81
Delivery of an anti-HIV-1 ribozyme into HIV-infected cells via cationic liposomes. Biochim Biophys Acta (1998) 0.81
Antisense catalytic RNAs as therapeutic agents. Adv Pharmacol (1994) 0.80
Small sequence insertions within the branch point region dictate alternative sites of lariat formation in a yeast intron. Nucleic Acids Res (1992) 0.80
A chimeric tRNA(Lys3)-ribozyme inhibits HIV replication following virion assembly. Nucleic Acids Symp Ser (1995) 0.80
Expression of hammerhead ribozymes by retroviral vectors to inhibit HIV-1 replication: comparison of RNA levels and viral inhibition. Antisense Nucleic Acid Drug Dev (1996) 0.79
Structural similarities between hammerhead ribozymes and the spliceosomal RNAs could be responsible for lack of ribozyme cleavage in yeast. Antisense Nucleic Acid Drug Dev (1998) 0.79
Procedure for isolating mutants defective in metabolite transport or utilization. J Bacteriol (1975) 0.79
Functional expression of a yeast ochre suppressor tRNA gene in Escherichia coli. Gene (1982) 0.78
Virion encapsidation of tRNA(3Lys)-ribozyme chimeric RNAs inhibits HIV infection. Antisense Nucleic Acid Drug Dev (1998) 0.78
PCR-based quantitation of low levels of HIV-1 DNA by using an external standard. Genet Anal Tech Appl (1992) 0.78
Unusual interactions between cleavage products of a cis-cleaving hammerhead ribozyme. Antisense Nucleic Acid Drug Dev (1998) 0.77
Topical antiviral siRNA: a practical siRNA microbicide? Gene Ther (2006) 0.77
Intracellular expression and function of antisense catalytic RNAs. Methods Enzymol (2000) 0.77
Anti-HIV therapy with antisense oligonucleotides and ribozymes: realistic approaches or expensive myths? J Antimicrob Chemother (1996) 0.77
Expression of the human immunodeficiency virus type 1 primer binding sequence inhibits HIV-1 replication. Hum Gene Ther (1998) 0.76
Hammerhead ribozyme-mediated cleavage of the human insulin-like growth factor-II ribonucleic acid in vitro and in prostate cancer cells. Endocrinology (1999) 0.76
Ribozymes expressed within the loop of a natural antisense RNA form functional transcription terminators. Gene (1995) 0.76
Functional colocalization of ribozymes and target mRNAs in Drosophila oocytes. FASEB J (2001) 0.76
Altered response to growth rate changes in Kluyveromyces lactis versus Saccharomyces cerevisiae as demonstrated by heterologous expression of ribosomal protein 59 (CRY1) Nucleic Acids Res (1991) 0.76
Delivery of novel macromolecular drugs against HIV-1. Expert Opin Biol Ther (2001) 0.75
Cooperative interaction of branch signals in the actin intron of Saccharomyces cerevisiae. Nucleic Acids Res (1998) 0.75
Enhanced inhibition of HIV-1 replication in macrophages by antisense oligonucleotides, ribozymes and acyclic nucleoside phosphonate analogs delivered in pH-sensitive liposomes. Nucleosides Nucleotides Nucleic Acids (2001) 0.75
Polymerase chain reaction detection of human immunodeficiency virus DNA in human periradicular lesions. J Endod (1994) 0.75
Structural components of an alcoholism treatment program. Evaluations by patients and staff. Q J Stud Alcohol (1974) 0.75
The relationship of MMPI subtype membership to demographic variables and treatment outcome among substance misusers. J Stud Alcohol (1983) 0.75
Antiviral applications of RNAi. Handb Exp Pharmacol (2006) 0.75
Medical offices subsidized by Cabrini Hospital, Chicago; hospital survival plan. Hosp Prog (1974) 0.75
Simple identification of mutant clones. Biotechniques (1999) 0.75
Selecting a CPA firm. Hosp Prog (1978) 0.75
Can alcoholism be treated in a mental hospital? Psychiatry Dig (1966) 0.75
Ribozyme-mediated inhibition of a Philadelphia chromosome-positive acute lymphoblastic leukemia cell line expressing the p190 bcr-abl oncogene. Biol Blood Marrow Transplant (1997) 0.75
Confirmation of HIV infection using gene amplification. Transfus Med Rev (1989) 0.75
Glass beads as a model matrix for solvent-deposition of drugs [proceedings]. J Pharm Pharmacol (1979) 0.75